Home › Funds › Decheng Capital LLC › LYEL

Decheng Capital LLC position in LYEL

LYELL IMMUNOPHARMA INC · Health Care

Decheng Capital LLC reported holding 692,050 shares of LYEL (LYELL IMMUNOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$6.8M, representing 0.99% of its reported portfolio and ranking #8 among its reported holdings. Decheng Capital LLC has disclosed LYEL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

Latest position (Q3 2026)692.05K sh
Reported value held$6.78M
Portfolio Weight0.99%
First reportedQ4 2024
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Decheng Capital LLC's LYEL position evolved

Decheng Capital LLC first disclosed a stake in LYEL in Q4 2024 at 11,909,341 shares (US$7.6M). The position peaked in Q4 2025 at 692,050 shares, worth US$21.3M. Across 8 filings, Decheng Capital LLC increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 692,050 shares valued at US$6.8M. Notable position changes include a 95% trim in Q2 2025 (shares rose 84% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2024 11.91M $7.62M New
Q1 2025 11.91M $6.41M Hold
Q2 2025 595.47K $5.26M Reduce
Q3 2025 595.47K $9.67M Hold
Q4 2025 692.05K $21.30M Add
Q1 2026 692.05K $13.88M Hold
Q2 2026 692.05K $9.72M Hold
Q3 2026 692.05K $6.78M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LYEL and 13F data

LYEL (LYELL IMMUNOPHARMA INC) is a Health Care company. 27 other funds we track also report a position in LYEL — the largest reported positions include ARCH Venture Management, LLC (US$45.5M), GSK plc (US$14.8M), Almitas Capital LLC (US$8.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LYEL

All LYEL fund holders →

FAQ

How long has Decheng Capital LLC held LYEL?

Decheng Capital LLC has disclosed LYEL holdings in 8 of the last 8 reported quarters, going back to Q4 2024.

What is Decheng Capital LLC's current position in LYEL?

As of Q3 2026, Decheng Capital LLC holds 692.05K shares of LYEL (LYELL IMMUNOPHARMA INC), valued at $6.78M, representing 0.99% of its reported portfolio and ranking #8.

Has Decheng Capital LLC been buying or selling LYEL?

In the latest 13F filing (Q3 2026), Decheng Capital LLC held unchanged its position in LYEL. The position peaked in Q4 2025 at 692.05K shares.

Which other funds hold LYEL?

Other major institutional holders of LYEL include ARCH Venture Management, LLC, GSK plc, Almitas Capital LLC, among 27 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.